Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Kestenberg-Messina Kaitlin M. 2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) COO and SVP, Compliance (Last) (First) (Middle) C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, 3. Date of Earliest Transaction (Month/Day/Year) 03/06/2026 (Street) BOCA RATON, FL 33487 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/06/2026 F 10,059(1) D $15.39 562,101 D Common Stock 03/07/2026 F 4,235(1) D $15.39 557,866 D Common Stock 03/09/2026 J(2) 91,266 D $ 0 466,600 D Common Stock 03/09/2026 M 2,500 A $5 469,100 D Common Stock 03/09/2026 M 1,250 A $4.31 470,350 D Common Stock 03/09/2026 M 2,646 A $2.83 472,996 D Common Stock 03/09/2026 M 1,525 A $2.35 474,521 D Common Stock 03/09/2026 M 2,175 A $1.55 476,696 D Common Stock 03/09/2026 S 10,096(3) D $15.63(4) 466,600(5)(6) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy)

$5

03/09/2026

M

2,500

(7)

02/14/2027

Common Stock

2,500

$ 0

2,500

D

Stock Option (right to buy)

$4.31

03/09/2026

M

1,250

(8)

06/05/2029

Common Stock

1,250

$ 0

1,250

D

Stock Option (right to buy)

$2.83

03/09/2026

M

2,646

(9)

08/19/2030

Common Stock

2,646

$ 0

2,771

D

Stock Option (right to buy)

$2.35

03/09/2026

M

1,525

(10)

02/25/2031

Common Stock

1,525

$ 0

2,225

D

Stock Option (right to buy)

$1.55

03/09/2026

M

2,175

(11)

07/19/2031

Common Stock

2,175

$ 0

2,825

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Kestenberg-Messina Kaitlin M. C/O ADMA BIOLOGICS, INC. 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON, FL 33487			COO and SVP, Compliance

Signatures

/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact		03/10/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
(2)	The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").
(3)	The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement.
(4)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
(5)	Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
(6)	(continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
(7)	The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested.
(8)	The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested.
(9)	The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested.
(10)	The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested.
(11)	The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.